The integration of automation and artificial intelligence (AI) technologies holds immense potential to revolutionise the drug discovery process, particularly through Centralised Compound Management (CCM).

Compound management organisations will need to up-scale current infrastructure, and outsource or create new paradigms to meet these requirements. This poster presents BioAscent's ongoing initiatives to advance automation and support AI-driven integrated drug discovery programmes, aiming to enhance efficiency and reduce costs for our customers' drug discovery programmes.